Loss of smell: a clinical marker of severe asthma

J. Castillo Vizuete (Barcelona, Spain), C. Picado (Barcelona, Spain), V. Plaza (Barcelona, Spain), G. Rodrigo (Montevideo, Uruguay), B. Juliá (Madrid, Spain), C. Fernandez (Madrid, Spain), J. Mullol (Barcelona , Spain)

Source: International Congress 2018 – Clinical markers of asthma
Session: Clinical markers of asthma
Session type: Thematic Poster
Number: 3984
Disease area: Airway diseases

Congress or journal article abstractE-poster

Abstract

Rhinitis and chronic rhinosinusitis (CRS) are frequently associated with asthma and CRS with severe asthma. Loss of smell (LoS) is associated with CRS, specially with nasal polyps.

We aimed to assess the reliability of LoS to discriminate severe from non-severe asthma and CRS from rhinitis.

In a cross-sectional study carried out in 2010-11 by pulmonologists and ENT specialists in 23 centers, asthmatic patients (N=383) were evaluated by GINA classification: 17.3% intermittent and 82.7% persistent (24.6% mild, 31.4% moderate, 26.7% severe) and by ARIA and EPOS: Half (49.6%) had rhinitis (37.0% AR and 12.6% NAR) and 36.2% CRS (16.7% CRSsNP; 19.5% CRSwNP) while 14.2% had no sinonasal disease. LoS was evaluated by severity (VAS scales, 0-100mm, median (IQR,Inter-Quartil Range)) and by prevalence of anosmia (hyposmia VAS >0-70MM, anosmia VAS >70mm).

LoS was present in 55.4% of asthma patients (hyposmia 41.5%, anosmia 14.9%). LoS severity was higher (22mm (0-75), p<0.001) and anosmia more frequent (26.4%, p<0.001) in severe persistent asthma than in moderate (10mm (0-50); 11.4%); mild (0mm (0-28); 10.7%), or intermittent asthma (0mm (0-45); 8.6%). In addition, LoS was more severe (38mm (2-76) vs. 0mm (0-45), p<0.001) and anosmia more frequent (28.1% vs. 3.9%, p<0.001) in CRS than in rhinitis, and even more severe (50mm (11-89) vs. 20mm (0-56), p<0.001) and anosmia more frequent (40.6% vs. 13.4%, p<0.001) in CRSwNP than in CRSsNP.

Loss of smell and specially the presence of anosmia may clearly discriminate severe from non-severe asthma and CRS (specially with nasal polyps) from rhinitis alone in asthma patients and may be considered a significant clinical marker of severe asthma.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Castillo Vizuete (Barcelona, Spain), C. Picado (Barcelona, Spain), V. Plaza (Barcelona, Spain), G. Rodrigo (Montevideo, Uruguay), B. Juliá (Madrid, Spain), C. Fernandez (Madrid, Spain), J. Mullol (Barcelona , Spain). Loss of smell: a clinical marker of severe asthma. 3984

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity
Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020
Year: 2021



Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice
Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019
Year: 2020



Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021



Clinical phenotypes of severe asthma: adults
Source: Eur Respir Monogr 2019; 84: 48-63
Year: 2019


Clinical phenotypes of severe asthma: children
Source: Eur Respir Monogr 2019; 84: 64-81
Year: 2019


Are acute exacerbation blood eosinophil numbers associated with clinical pattern of preschool wheeze?
Source: International Congress 2015 – More paediatric asthma and allergy
Year: 2015


Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011


Defining the clinical clusters of severe asthma within UBIOPRED
Source: International Congress 2015 – Fingerprinting severe asthma
Year: 2015



Chronic cough and sputum production: a clinical COPD phenotype?
Source: Eur Respir J 2012; 40: 4-6
Year: 2012


Improved definition of severe asthma phenotypes
Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop
Year: 2014




Evolution from mild to severe asthma; the severe asthma clinic perspective
Source: International Congress 2019 – Clinical implications of asthma management
Year: 2019


Complex lung function in severe asthma: seeing is believing
Source: Eur Respir J 2016; 48: 294-296
Year: 2016


Only severe asthma?
Source: International Congress 2019 – PG11 Severe paediatric asthma
Year: 2019


The frequent exacerbator phenotype in asthma: a clinical characterization
Source: Virtual Congress 2020 – Phenotypes of obstructive diseases
Year: 2020


Difficult-to-treat asthma: how serious is the problem and what are the issues?
Source: Eur Respir Mon 2011; 51: 1-15
Year: 2011


Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 335s
Year: 2001

The clinical features of asthma-COPD overlap syndrome compared to asthma with irreversible airway obstruction
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015


Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis?
Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy
Year: 2017

Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021


Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?
Source: Eur Respir J, 50 (6) 1701366; 10.1183/13993003.01366-2017
Year: 2017